Lung cancer working group report

Asia needs a guideline for non-small-cell lung cancer because of differences in medical care, medical care insurance, ethnic variation and drug approval lag within Asian countries and compared with Western countries. Due to ethnic differences, drug dosages are often higher in the USA than in Japan....

Full description

Saved in:
Bibliographic Details
Main Authors: Nagahiro Saijo, Masahiro Fukuoka, Sumitra Thongprasert, Yukito Ichinose, Tetsuya Mitsudomi, Tony Shu Kam Mok, Yuichiro Ohe, Keunchil Park, Yi Long Wu
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77957280882&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/50547
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-50547
record_format dspace
spelling th-cmuir.6653943832-505472018-09-04T04:50:42Z Lung cancer working group report Nagahiro Saijo Masahiro Fukuoka Sumitra Thongprasert Yukito Ichinose Tetsuya Mitsudomi Tony Shu Kam Mok Yuichiro Ohe Keunchil Park Yi Long Wu Biochemistry, Genetics and Molecular Biology Medicine Asia needs a guideline for non-small-cell lung cancer because of differences in medical care, medical care insurance, ethnic variation and drug approval lag within Asian countries and compared with Western countries. Due to ethnic differences, drug dosages are often higher in the USA than in Japan. EGFR mutation in non-small-cell lung cancer was detected in 32% of Asians but only 6% of non-Asians, while differences in irinotecan metabolism cause higher frequencies of toxicity (leukopenia, diarrhea) in Asians. Pharmacodynamic ethnic differences in relation to paclitaxel/carboplatin resulted in longer median survival and a higher 1-year survival rate for Japanese-advanced non-small-cell lung cancer patients compared with Americans. To solve the problem of drug lag, pharmaceutical companies must perform multinational Asian clinical trials with quick accrual of patients, while regulatory authorities must establish high-quality, efficient approval processes, and achieve regulatory harmonization. The National Comprehensive Cancer Network promotes creation of national clinical practice guidelines, and Korea, China and Thailand adapted the National Comprehensive Cancer Network guidelines. Many Asian countries still lack such guidelines, and there are no pan-Asian guidelines for non-small-cell lung cancer. Japan developed its own non-small-cell lung cancer guidelines and also a gefitinib guidance. The study group members concluded that immediate establishment of an Asian non-small-cell lung cancer guideline will be difficult because of the differences among the countries. Asian collaborative trials on treatment of non-small-cell lung cancer need to be started at an early date to generate Asian data. © The Author (2010). Published by Oxford University Press. All rights reserved. 2018-09-04T04:42:13Z 2018-09-04T04:42:13Z 2010-09-01 Journal 14653621 03682811 2-s2.0-77957280882 10.1093/jjco/hyq121 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77957280882&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/50547
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Biochemistry, Genetics and Molecular Biology
Medicine
spellingShingle Biochemistry, Genetics and Molecular Biology
Medicine
Nagahiro Saijo
Masahiro Fukuoka
Sumitra Thongprasert
Yukito Ichinose
Tetsuya Mitsudomi
Tony Shu Kam Mok
Yuichiro Ohe
Keunchil Park
Yi Long Wu
Lung cancer working group report
description Asia needs a guideline for non-small-cell lung cancer because of differences in medical care, medical care insurance, ethnic variation and drug approval lag within Asian countries and compared with Western countries. Due to ethnic differences, drug dosages are often higher in the USA than in Japan. EGFR mutation in non-small-cell lung cancer was detected in 32% of Asians but only 6% of non-Asians, while differences in irinotecan metabolism cause higher frequencies of toxicity (leukopenia, diarrhea) in Asians. Pharmacodynamic ethnic differences in relation to paclitaxel/carboplatin resulted in longer median survival and a higher 1-year survival rate for Japanese-advanced non-small-cell lung cancer patients compared with Americans. To solve the problem of drug lag, pharmaceutical companies must perform multinational Asian clinical trials with quick accrual of patients, while regulatory authorities must establish high-quality, efficient approval processes, and achieve regulatory harmonization. The National Comprehensive Cancer Network promotes creation of national clinical practice guidelines, and Korea, China and Thailand adapted the National Comprehensive Cancer Network guidelines. Many Asian countries still lack such guidelines, and there are no pan-Asian guidelines for non-small-cell lung cancer. Japan developed its own non-small-cell lung cancer guidelines and also a gefitinib guidance. The study group members concluded that immediate establishment of an Asian non-small-cell lung cancer guideline will be difficult because of the differences among the countries. Asian collaborative trials on treatment of non-small-cell lung cancer need to be started at an early date to generate Asian data. © The Author (2010). Published by Oxford University Press. All rights reserved.
format Journal
author Nagahiro Saijo
Masahiro Fukuoka
Sumitra Thongprasert
Yukito Ichinose
Tetsuya Mitsudomi
Tony Shu Kam Mok
Yuichiro Ohe
Keunchil Park
Yi Long Wu
author_facet Nagahiro Saijo
Masahiro Fukuoka
Sumitra Thongprasert
Yukito Ichinose
Tetsuya Mitsudomi
Tony Shu Kam Mok
Yuichiro Ohe
Keunchil Park
Yi Long Wu
author_sort Nagahiro Saijo
title Lung cancer working group report
title_short Lung cancer working group report
title_full Lung cancer working group report
title_fullStr Lung cancer working group report
title_full_unstemmed Lung cancer working group report
title_sort lung cancer working group report
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77957280882&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/50547
_version_ 1681423609513377792